When Pamela Keck, vice president of investor relations and corporate communications at German biotech Medigene, took up her role on February 1 this year, there was plenty to do. Her position had been unfilled for a number of months and executives were eager for her to hit the ground running. ‘There was no honeymoon period,’ she jokes to IR Magazine.
Thankfully, it wasn’t the first time Keck had arrived in a new IR role – far from it, in fact. Over the last 15 years, she has set up or taken over IR departments at several listed companies, both in . . .
Log in FOR FREE to access this content
Log in or create your free My IR – Essentials account to:
- Access 50+ deep dives and best practice reports
- View 100+ news analyses and our exclusive CFO series
- Instantly benchmark your IR program with our new tool
- Save favorites and get tailored content delivered to your dashboard
- 10% off all IR forums!
Join now to make a real impact in your organization.
